Q-omics provides the consensus-scored LRFN1 profile across patient tissues and cancer cell-line models. LRFN1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LRFN1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LRFN1 RNA expression shows 16,326 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KIRC, and THYM as cancer lineages where LRFN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRFN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRFN1 survival associations across molecular data types. LRFN1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRFN1 RNA expression–survival associations across cancer types. High LRFN1 expression shows unfavorable associations in COAD, STAD, UCEC, KIRC, OV and KIRP. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LRFN1 RNA expression.
This table summarizes LRFN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LRFN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRFN1 shows lower tumor expression in THCA and COAD and higher tumor expression in KIRC, HNSC, LUSC and BRCA. The KIRC box plot shows higher LRFN1 RNA expression in tumor versus normal tissue (log2 FC = +0.634, t-test p < 0.001).
This table shows molecular features associated with LRFN1 in patient tissues and cancer cell lines. In patient samples, LRFN1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRFN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
